ZEALAND PHARMA A/S (22Z.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:22Z - DK0060257814 - Common Stock
69.76 EUR
-0.56 (-0.8%)
We assign a fundamental rating of 7 out of 10 to 22Z. 22Z was compared to 81 industry peers in the Biotechnology industry. While 22Z has a great health rating, its profitability is only average at the moment. 22Z has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes 22Z very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
22Z had positive earnings in the past year.
In the past year 22Z had a positive cash flow from operations.
22Z had negative earnings in each of the past 5 years.
22Z had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 38.95%, 22Z belongs to the top of the industry, outperforming 97.53% of the companies in the same industry.
22Z's Return On Equity of 43.15% is amongst the best of the industry. 22Z outperforms 98.77% of its industry peers.
22Z has a Return On Invested Capital of 32.76%. This is amongst the best in the industry. 22Z outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.95% | ||
| ROE | 43.15% | ||
| ROIC | 32.76% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
22Z's Profit Margin of 71.47% is amongst the best of the industry. 22Z outperforms 97.53% of its industry peers.
22Z's Operating Margin of 79.38% is amongst the best of the industry. 22Z outperforms 98.77% of its industry peers.
22Z has a Gross Margin of 99.99%. This is amongst the best in the industry. 22Z outperforms 97.53% of its industry peers.
22Z's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 79.38% | ||
| PM (TTM) | 71.47% | ||
| GM | 99.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
2. Health
2.1 Basic Checks
22Z has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
22Z has more shares outstanding than it did 1 year ago.
22Z has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 22Z has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 11.93 indicates that 22Z is not in any danger for bankruptcy at the moment.
22Z has a better Altman-Z score (11.93) than 88.89% of its industry peers.
The Debt to FCF ratio of 22Z is 0.06, which is an excellent value as it means it would take 22Z, only 0.06 years of fcf income to pay off all of its debts.
22Z has a Debt to FCF ratio of 0.06. This is amongst the best in the industry. 22Z outperforms 96.30% of its industry peers.
22Z has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
22Z's Debt to Equity ratio of 0.03 is fine compared to the rest of the industry. 22Z outperforms 69.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 11.93 |
ROIC/WACC4.72
WACC6.94%
2.3 Liquidity
A Current Ratio of 14.10 indicates that 22Z has no problem at all paying its short term obligations.
22Z has a Current ratio of 14.10. This is amongst the best in the industry. 22Z outperforms 95.06% of its industry peers.
A Quick Ratio of 14.10 indicates that 22Z has no problem at all paying its short term obligations.
The Quick ratio of 22Z (14.10) is better than 95.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.1 | ||
| Quick Ratio | 14.1 |
3. Growth
3.1 Past
22Z shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 661.53%, which is quite impressive.
22Z shows a strong growth in Revenue. In the last year, the Revenue has grown by 11809.72%.
The Revenue has been growing by 8.69% on average over the past years. This is quite good.
EPS 1Y (TTM)661.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.52%
Revenue 1Y (TTM)11809.72%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%1022.74%
3.2 Future
22Z is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.04% yearly.
The Revenue is expected to grow by 122.10% on average over the next years. This is a very strong growth
EPS Next Y652.64%
EPS Next 2Y77.48%
EPS Next 3Y13.19%
EPS Next 5Y0.04%
Revenue Next Year11614.8%
Revenue Next 2Y668.41%
Revenue Next 3Y251.45%
Revenue Next 5Y122.1%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.60 indicates a rather cheap valuation of 22Z.
Based on the Price/Earnings ratio, 22Z is valued cheaply inside the industry as 95.06% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of 22Z to the average of the S&P500 Index (26.11), we can say 22Z is valued rather cheaply.
A Price/Forward Earnings ratio of 27.85 indicates a quite expensive valuation of 22Z.
Based on the Price/Forward Earnings ratio, 22Z is valued cheaply inside the industry as 81.48% of the companies are valued more expensively.
22Z is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.6 | ||
| Fwd PE | 27.85 |
4.2 Price Multiples
22Z's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 22Z is cheaper than 97.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.26 | ||
| EV/EBITDA | -0.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
22Z's earnings are expected to grow with 13.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y77.48%
EPS Next 3Y13.19%
5. Dividend
5.1 Amount
No dividends for 22Z!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:22Z (11/28/2025, 7:00:00 PM)
69.76
-0.56 (-0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners48.71%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap3.22B
Revenue(TTM)9.16B
Net Income(TTM)6.54B
Analysts84.8
Price Target104.6 (49.94%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.92%
Min EPS beat(2)-5.54%
Max EPS beat(2)31.39%
EPS beat(4)2
Avg EPS beat(4)-143.51%
Min EPS beat(4)-623.11%
Max EPS beat(4)31.39%
EPS beat(8)3
Avg EPS beat(8)-73.88%
EPS beat(12)5
Avg EPS beat(12)-38.79%
EPS beat(16)7
Avg EPS beat(16)-27.86%
Revenue beat(2)1
Avg Revenue beat(2)21.02%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)45.58%
Revenue beat(4)1
Avg Revenue beat(4)-24.03%
Min Revenue beat(4)-74.61%
Max Revenue beat(4)45.58%
Revenue beat(8)4
Avg Revenue beat(8)20.68%
Revenue beat(12)7
Avg Revenue beat(12)58.52%
Revenue beat(16)7
Avg Revenue beat(16)31.76%
PT rev (1m)-4.28%
PT rev (3m)N/A
EPS NQ rev (1m)-46.13%
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.62%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-22.21%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.6 | ||
| Fwd PE | 27.85 | ||
| P/S | 2.62 | ||
| P/FCF | 3.26 | ||
| P/OCF | 3.25 | ||
| P/B | 1.58 | ||
| P/tB | 1.59 | ||
| EV/EBITDA | -0.26 |
EPS(TTM)12.45
EY17.85%
EPS(NY)2.5
Fwd EY3.59%
FCF(TTM)21.4
FCFY30.68%
OCF(TTM)21.47
OCFY30.77%
SpS26.58
BVpS44.02
TBVpS43.98
PEG (NY)0.01
PEG (5Y)N/A
Graham Number111.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.95% | ||
| ROE | 43.15% | ||
| ROCE | 46.53% | ||
| ROIC | 32.76% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 79.38% | ||
| PM (TTM) | 71.47% | ||
| GM | 99.99% | ||
| FCFM | 80.53% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
F-Score8
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.06 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | 86.21% | ||
| Cap/Sales | 0.24% | ||
| Interest Coverage | 432.5 | ||
| Cash Conversion | 101.39% | ||
| Profit Quality | 112.67% | ||
| Current Ratio | 14.1 | ||
| Quick Ratio | 14.1 | ||
| Altman-Z | 11.93 |
F-Score8
WACC6.94%
ROIC/WACC4.72
Cap/Depr(3y)51.82%
Cap/Depr(5y)53.82%
Cap/Sales(3y)13.05%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)661.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.52%
EPS Next Y652.64%
EPS Next 2Y77.48%
EPS Next 3Y13.19%
EPS Next 5Y0.04%
Revenue 1Y (TTM)11809.72%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%1022.74%
Revenue Next Year11614.8%
Revenue Next 2Y668.41%
Revenue Next 3Y251.45%
Revenue Next 5Y122.1%
EBIT growth 1Y751.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year744.74%
EBIT Next 3Y22.1%
EBIT Next 5Y17.81%
FCF growth 1Y1048.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1076.19%
OCF growth 3YN/A
OCF growth 5YN/A
ZEALAND PHARMA A/S / 22Z.DE FAQ
What is the ChartMill fundamental rating of ZEALAND PHARMA A/S (22Z.DE) stock?
ChartMill assigns a fundamental rating of 7 / 10 to 22Z.DE.
What is the valuation status of ZEALAND PHARMA A/S (22Z.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to ZEALAND PHARMA A/S (22Z.DE). This can be considered as Undervalued.
What is the profitability of 22Z stock?
ZEALAND PHARMA A/S (22Z.DE) has a profitability rating of 5 / 10.
What is the valuation of ZEALAND PHARMA A/S based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ZEALAND PHARMA A/S (22Z.DE) is 5.6 and the Price/Book (PB) ratio is 1.58.
What is the financial health of ZEALAND PHARMA A/S (22Z.DE) stock?
The financial health rating of ZEALAND PHARMA A/S (22Z.DE) is 9 / 10.